Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 10Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 4Uterine Cervical Neoplasms 3Uterine Cervical Dysplasia 3Glioma 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Brain Neoplasms 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Rectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Oropharyngeal Neoplasms 2Neoplasms 2Mouth Neoplasms 2Melanoma 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Ependymoma 2Uveal Melanoma 1Uterine Neoplasms 1Uterine Diseases 1Uterine Cervical Diseases 1Urogenital Neoplasms 1Urogenital Diseases 1Ureteral Neoplasms 1Thyroid Nodule 1

Interventions

Watchful Waiting 1Vincristine 1Topotecan 1Specimen Handling 1Razoxane 1Observation 1Magnetic Resonance Spectroscopy 1Ifosfamide 1High-Energy Shock Waves 1Doxorubicin 1Dexrazoxane 1Dactinomycin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pleuropulmonary blastoma × Watchful Waiting × 1 year × Clear all
NCT06647953 2026-05-05

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

Children's Oncology Group

Phase 3 Recruiting
110 enrolled

Pleuropulmonary blastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡